You may qualify for a Mounjaro eye-injury claim if you used tirzepatide before sudden vision loss and then received a formal NAION diagnosis. NAION is an irreversible eye condition that can cause permanent partial or complete vision loss. Screening lawyers focus on prescription timing, eye records, and pharmacy records.
Parker Waichman announced in a PR Newswire release that it sued on behalf of a Texas resident with that pattern after Mounjaro use. Federal vision-loss cases are now grouped for pretrial handling. No settlement exists.
Official resources:
- Read the official guidance from Prnewswire — Use this primary source to verify the official guidance.
- Check eligibility on Motleyrice’s official study page — Use this page to check the study’s participation requirements.
Table of Contents
- What eye injury is at issue?
- What prescription history matters?
- Where do federal cases stand?
- What does the eye research show?
- What should you do next?
What eye injury is at issue?
The injury is NAION, a sudden loss of blood flow to the optic nerve. It can cause abrupt blurring, dimming, blind spots, or loss of part of the visual field. The Texas case alleges permanent partial or complete vision loss after Mounjaro.
A qualifying claim needs more than poor vision while on the drug. Firms look for a formal NAION diagnosis from an eye specialist. That diagnosis usually comes after an urgent exam, visual-field testing, and optic-nerve evaluation.
What prescription history matters?
Mounjaro is Eli Lilly's once-weekly tirzepatide injection. FDA DailyMed information cited for August 2026 describes approval on May 13, 2022 as an add-on to diet and exercise for type 2 diabetes in adults and children age 10 and older. Motley Rice explains in its tirzepatide litigation overview that screening looks for a documented tirzepatide prescription before sudden vision loss.
The central allegation is failure to warn about NAION risk. Keep every pharmacy fill record, dosage change, and date of first use. Useful records include:.
- dated prescription and refill history showing use before vision change
- ophthalmology notes with a stated NAION diagnosis
- emergency or primary-care notes describing onset and symptoms
- pharmacy records linking product, dose, and timing
Where do federal cases stand?
Vision-loss claims are proceeding separately from stomach and intestinal claims. Licatesi Law Group reports consolidation on December 15, 2025 as MDL 3163 before Judge Karen S. Marston in the Eastern District of Pennsylvania, apart from gastrointestinal-injury MDL 3094.
The Lanier Law Firm stated in a November 2026 update that MDL 3163 had grown to 278 active federal cases. Those cases allege Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 drugs caused sudden permanent NAION vision loss. MDL treatment coordinates discovery, not payment.
What does the eye research show?
A July 3, 2024 JAMA Ophthalmology matched cohort from Massachusetts Eye and Ear is widely cited in the debate. The American Academy of Ophthalmology and NANOS consensus summary reports semaglutide hazard ratios of 4.28 in type 2 diabetes and 7.64 in overweight or obesity.
Europe has acted on labeling for a related drug. Europe's medicines regulator concluded in a June 2025 announcement that NAION is a very rare semaglutide side effect, affecting up to 1 in 10,000 users. It estimated about one extra case per 10,000 person-years and required EU label updates.
What should you do next?
Sudden vision loss needs urgent eye care. Do not stop diabetes medicine on your own without medical advice. Medical Daily's November 2025 reporting notes U.S.
labels warn about diabetic-retinopathy complications but not NAION while FDA Sentinel review continues. Preserve the paper trail before contacting a firm. Save the drug box, remaining pens, receipts, appointment cards, imaging discs, and work-absence notes. Write down when vision changed, which eye was affected, and who examined you.